XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information

3. Segment Information

 

The Company’s chief operating decision maker (“CODM”) has been identified as the Company’s President and Chief Executive Officer (“CEO”). The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it has a single operating segment composed of the consolidated financial results of the Company.

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs.

 

   2025   2024 
   Three Months Ended March 31, 
   2025   2024 
         
Compensation to related parties:          
Cash-based  $108,731   $214,735 
Stock-based   99,738    102,927 
Patent and licensing legal and filing fees and costs   56,084    83,211 
Other consulting and professional fees   205,315    172,443 
Insurance expense   64,277    126,854 
Other costs and expenses, net   81,338    147,645 
Total general and administrative costs  $615,483   $847,815 

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in research and development costs.

 

   2025   2024 
   Three Months Ended March 31, 
   2025   2024 
         
Clinical and related oversight costs  $15,868   $10,030 
Preclinical research focused on development of additional novel anti-cancer compounds   42,770    104,480 
Compound Maintenance   32,819    3,894 
Regulatory service costs       660 
Total research and development costs  $91,457   $119,064 

 

The following table presents a summary of research and development costs for the three months ended March 31, 2025 and 2024 based on the respective geographical regions where such costs were incurred.

 

 

   2025   2024 
   Three Months Ended March 31, 
   2025   2024 
         
United States  $58,571   $34,583 
Spain   32,886    15,234 
China       2,282 
Netherlands       66,965 
Total  $91,457   $119,064 

 

The following table presents the Company’s total assets by segment at March 31, 2025 and December 31, 2024.

 

  

March 31,

2025

   December 31,
2024
 
         
Research and development assets  $29,669   $39,298 
Corporate assets   1,484,559    1,106,205 
Total assets  $1,514,228   $1,145,503